Valuation: Emergent BioSolutions Inc.

Market Cap 266M 228M 213M 195M 368M 25.32B 371M 2.52B 979M 12.77B 997M 976M 42.31B P/E 2026 *
-1.12x
P/E 2027 * 78.1x
Enterprise Value 636M 545M 510M 466M 880M 60.61B 889M 6.02B 2.34B 30.58B 2.39B 2.34B 101B EV / Sales 2026 *
0.97x
EV / Sales 2027 * 0.82x
Free-Float
43.38%
Yield 2026 *
-
Yield 2027 * -
1 day+4.54%
1 week+15.99%
Current month-25.14%
1 month-26.26%
3 months-40.80%
6 months-50.91%
Current year-56.27%
1 week 4.58
Extreme 4.58
5.49
1 month 4.36
Extreme 4.36
7.7
Current year 4.36
Extreme 4.36
14.06
1 year 4.36
Extreme 4.36
14.06
3 years 1.42
Extreme 1.42
15.1
5 years 1.42
Extreme 1.42
65.09
10 years 1.42
Extreme 1.42
137.61
Manager TitleAgeSince
Chief Executive Officer 70 21/02/2024
Director of Finance/CFO 62 26/03/2018
Compliance Officer 55 01/03/2020
Director TitleAgeSince
Chairman 82 01/04/2022
Director/Board Member 70 01/01/2005
Director/Board Member 77 01/10/2016
Date Insider Type Main position Quantity % Market Cap.
8/5/26 A Other

Executive/Senior Manager

455,311 0.8824%
7/1/26 A Sell

Executive/Senior Manager

-3,000 0.0058%
4/29/26 A Free

Executive/Senior Manager

100,111 0.1934%
Change 5-day change 1-year change 3-year change Capi.($)
+4.54%+15.99%-41.25%+19.05% 266M
+0.16%+2.35%+80.42%+126.59% 1,111B
+0.41%+0.68%+53.00%+64.19% 658B
+0.59%+2.70%+28.12%+81.28% 467B
+0.92%+3.57%+43.82%+44.21% 369B
+1.25%+2.21%+26.77%+43.05% 301B
+3.02%+5.68%+5.09%+17.04% 256B
+0.12%+4.36%+53.86%+73.12% 240B
+2.86%+3.86%-16.20%-51.83% 207B
+0.66%+2.84%+29.22%+91.92% 182B
Average +1.48%+5.11%+26.28%+50.86% 379.13B
Weighted average by Cap. +0.81%+4.68%+46.89%+73.35%

Financials

2026 *2027 *
Net sales 657M 563M 528M 482M 910M 62.65B 919M 6.22B 2.42B 31.61B 2.47B 2.41B 105B 703M 603M 565M 516M 974M 67.05B 983M 6.66B 2.59B 33.83B 2.64B 2.58B 112B
Net income -239M -205M -192M -175M -331M -22.8B -334M -2.27B -882M -11.5B -898M -879M -38.1B 3.48M 2.98M 2.79M 2.55M 4.81M 331M 4.86M 32.92M 12.82M 167M 13.05M 12.77M 554M
Net Debt 370M 317M 297M 271M 512M 35.29B 517M 3.51B 1.36B 17.8B 1.39B 1.36B 58.96B 309M 265M 248M 227M 428M 29.44B 432M 2.93B 1.14B 14.86B 1.16B 1.13B 49.2B
Logo Emergent BioSolutions Inc.
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Employees
900
Date Price Change Volume
25/08/26 $5.405 +4.34% 399,271
24/08/26 $5.180 +1.97% 871,184
21/08/26 $5.080 +5.39% 1,418,590
20/08/26 $4.820 -1.43% 1,509,459
19/08/26 $4.890 +4.94% 1,593,454
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.180USD
Average target price
11.00USD
Spread / Average Target
+112.36%

Quarterly revenue - Rate of surprise